Abiraterone amorphous solid dispersion formulation DST-2970

{
  "id": "MLC-T-ONC-009580",
  "term": "Abiraterone amorphous solid dispersion formulation DST-2970",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels.",
  "synonyms": [
    "abiraterone KinetiSol formulation DST-2970"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/abiraterone-amorphous-solid-dispersion-formulation-dst-2970/"
}